钱峰：博士，教授，博士生导师，科研副院长。2006年在南京大学生命科学院获得博士学位，2006年至2011年，在美国伊利诺伊大学药理学系从事博士后研究工作，并于2011年3月晋升为研究助理教授，2013年回国在15vip太阳集团任课题组组长。主要研究方向为免疫药理学、分子药理学、肿瘤药理学、神经药理学和抗体工程；聚焦巨噬细胞极化的泛素化修饰、代谢性调控、转录因子激活等分子机制；阐明感染性肺炎、过敏性哮喘、肺纤维化、老年痴呆症、抑郁症等复杂性疾病的发病机理；鉴定潜在药物作用靶标、研发小分子药物及治疗性抗体药物。以通讯作者在Nature Microbiology，Nature Communication，Journal of Experimental Medicine等国际著名学术杂志上发表研究论文60余篇。中国药理学会抗炎免疫药理专业委员会委员和青年委员会常务委员，上海药学会药理专业委员会委员，上海市药物代谢研究中心理事，世中联中医药免疫专委会常务理事，美国心血管学会、美国生理学会、美国胸科学会，美国免疫学家学会等学会会员。主持国家自然科学基金面上项目6项，国家重点研发计划“精准医学研究”专项1项（分项目负责人），作为骨干参与重大专项“重大新药创制”1项。担任《人民卫生出版社中国医学教育题库》药理学学科副主编。

教学情况：
1. 主讲研究生《高等药理学》和《免疫药理学》。
2. 主讲本科生《基因与健康》。

本课题组招聘博士后，研究方向是抗炎免疫，主要任务从临床样本分析，动物模型建立，细胞功能检测，信号通路解析，系统阐明炎症性疾病的病理机制，鉴定新型药物作用靶标。

Dr. Feng Qian: Ph.D. and M.D., Professor, Doctoral Supervisor and Vice Dean of the School of Pharmacy, Shanghai Jiao Tong University. His main research interests include immunopharmacology, molecular pharmacology, tumor pharmacology, neuropharmacology, and antibody engineering. His research focuses on molecular mechanisms such as ubiquitination modification, metabolic regulation, and transcription factor activation in macrophage polarization. He elucidates the pathogenesis of complex diseases, such as infectious pneumonia, allergic asthma, pulmonary fibrosis, Alzheimer's disease, and depression. Additionally, he identifies several potential drug targets, develops small molecule drugs, and therapeutic antibodies. As corresponding author, he has published over 60 research papers in internationally renowned academic journals, including Nature Microbiology, Nature Communication, and the Journal of Experimental Medicine. He is a member and executive committee member of the Anti-inflammatory and Immunopharmacology Professional Committee and the Youth Committee of the Chinese Pharmacological Society, a member of the Pharmacology Professional Committee of the Shanghai Pharmaceutical Society, Director of the Shanghai Drug Metabolism Research Center, an Executive Director of the Immunotherapy Committee of the World Federation of Chinese Medicine Societies, and a member of various American societies, such as the American Heart Association, the American Physiological Society, the American Thoracic Society, and the American Association of Immunologists. He has presided over 6 projects of the National Natural Science Foundation of China and one key research and development program under the "Precision Medicine Research" special project (as a sub-project leader), and has participated as a core member in one major project on "Major New Drug Development." He serves as the associate editor for the subject of Pharmacology.

1. 聚焦巨噬细胞极化分子机制，重点关注肺泡巨噬细胞等组织驻留巨噬细胞的生理性和病理性功能，阐明泛素化修饰、能量代谢、转录因子激活、磷酸化修饰等信号对于巨噬细胞的活化作用；
2. 聚焦感染性肺炎、过敏性哮喘、肺纤维化、肺癌等呼吸系统疾病的机制研究与药物靶标发现，揭示肺部炎症微环境调控呼吸系统疾病的病理机制；
3. 聚焦恶性肿瘤的免疫机制与药物发现，揭示肿瘤相关巨噬细胞（TAM）介导的炎症微环境调控肿瘤的病理机制；
4. 聚焦抗体药物研发体系和药物筛选体系搭建，通过抗体制备技术、细胞工程技术和高通量药物筛选技术研发创新药物；
5. 建立新型肿瘤免疫、过敏性疾病、神经系统疾病、炎症性疾病、消化系统疾病等新型疾病模型，用于体内药物筛选和药效学评价。

1. Determine the molecular mechanisms of macrophage polarization, with a particular emphasis on the physiological and pathological functions of tissue-resident macrophages such as alveolar macrophages. Elucidate the several signaling pathways, including ubiquitination modification, energy metabolism, transcription factor activation, and phosphorylation modification in macrophages.
2. Focus on respiratory system diseases such as infectious pneumonia, allergic asthma, pulmonary fibrosis, and lung cancer, revealing the pathological mechanisms of respiratory system diseases regulated by the pulmonary inflammatory microenvironment.
3. the immune mechanisms and drug discovery of malignant tumors, revealing the pathological mechanisms of tumor regulation mediated by tumor-associated macrophages (TAM) in the inflammatory microenvironment.
4. Focus on establishing the development system for antibody drugs and drug screening, utilizing antibody preparation technology, cell engineering technology, and high-throughput drug screening technology to develop innovative drugs.
5. Establish novel disease models for tumor immunity, allergic diseases, neurological disorders, inflammatory diseases, and digestive system diseases, to be used for in vivo drug screening and pharmacological evaluation.

以通讯作者发表的代表性研究论文（Representative research papers published as corresponding author）：
1. Lei Sun*, Haibo Zhang, Huihui Zhang, Xinyi Lou, Zhiming Wang, Yaxian Wu, Xinyi Yang, Daijie Chen, Beining Guo, Ao Zhang, Feng Qian*. Intracellular Staphylococcus aureus utilizes endoplasmic reticulum-resident E3 ubiquitin ligase AMFR to promote pneumonia via virulent -hemolysin B. Nature Microbiology. 2023, 8: 107-120 doi :10.1038/s41564-022-01278-7. (IF: 30.964, 通讯作者)
2. Huihui Zhang, Ran Wei, Xinyi Yang, Lu Xu, Hongchao Jiang, Mengkai Li, Haixia Jiang, haibo Zhang, Zhihong Chen, Feng Qian *, Lei Sun *. AMFR drives allergic asthma development by promoting alveolar macrophage-derived GM-CSF production. Journal of Experimental Medicine 2022 May 2;219(5): e20211828. doi: 10.1084/jem.20211828. (IF: 17.579, 通讯作者)
3. Dongxin Chen, Huirong Tang, Hongchao Jiang, Lei Sun, Wenjuan Zhao, Feng Qian*. ACPA Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-β-Smad2/3 Signaling-Mediated Lung Fibroblast Activation. Front Pharmacol. 2022 Mar 9;13:835979. doi: 10.3389/fphar.2022.835979. PMID: 35355726; PMCID: PMC8959577.
4. Hongchao Jiang, Yaxue Zhao, Huirong Tang, Shixin Duan, Mengkai Li, Xinyi Yang, Jingting Liu, Xinyi Lou, Yuanyuan Cai, Wenjuan Zhao, Lei Sun*, Feng Qian *. Tetraethylthiuram disulphide alleviates pulmonary fibrosis through modulating transforming growth factor-β signalling. Pharmacol Res. 2021 Dec;174:105923. doi: 10.1016/j.phrs.2021.105923. Epub 2021 Oct 1. PMID: 34607006. (IF: 10.334, 通讯作者)
5. Hai-Feng Zhang, Hai-Bo Zhang, Xue-Ping Wu, Ya-Ling Guo, Wei-Dong Cheng, Feng Qian*. Fisetin alleviates sepsis-induced multiple organ dysfunction in mice via inhibiting p38 MAPK/MK2 signaling. Acta Pharmacol Sin. 2020 Oct;41(10):1348-1356. doi: 10.1038/s41401-020-0462-y. Epub 2020 Jul 13. PMID: 32661350; PMCID: PMC7608145.
6. Qing Liang, Wuyang Cai , Yaxue Zhao, Huanbai Xu, Huirong Tang, Daijie Chen, Feng Qian*, Lei Sun*. Lycorine ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3 inflammasome activation and pyroptosis. Pharmacol Res. 2020 Aug;158:104884. doi: 10.1016/j.phrs.2020.104884. Epub 2020 May 16. PMID: 32428667.
7. Xingli Li, Chenxian Ye, Mubarak Mulati, Lei Sun*, Feng Qian*. Ellipticine blocks synergistic effects of IL-17A and TNF-α in epithelial cells and alleviates severe acute pancreatitis-associated acute lung injury. Biochem Pharmacol. 2020 Jul;177:113992. doi: 10.1016/j.bcp.2020.113992. Epub 2020 Apr 23. PMID: 32335141.
8. Zishu Wang, Kaikai Yu, Yudong Hu, Fang Su, Zhenyuan Gao, Ting Hu, Yang Yang, Xiangliao Cao, Feng Qian*. Schisantherin A induces cell apoptosis through ROS/JNK signaling pathway in human gastric cancer cells. Biochem Pharmacol. 2020 Mar;173:113673. doi: 10.1016/j.bcp.2019.113673. Epub 2019 Oct 17. PMID: 31629709.
9. Li-Nian Huang, Lei Sun, Li-Ming Liu, Hui-Hui Zhang, Zhong-Bo Liang, Yan Rui, Jun-Feng Hu, Yong Zhang, John W Christman*, Feng Qian*. p38α MAP kinase promotes asthmatic inflammation through modulation of alternatively activated macrophages. J Mol Cell Biol. 2019 Dec 19;11(12):1095-1097. doi: 10.1093/jmcb/mjz054. PMID: 31253986; PMCID: PMC6934154.
10. Lei Sun, Qiong Wu, Yunjuan Nie, Ni Cheng, Rui Wang, Gang Wang, Dan Zhang, Huiqion He, Richard D. Ye and Feng Qian*. A Role for MK2 in Enhancing Neutrophil-Derived ROS Production and Aggravating Liver Ischemia/Reperfusion Injury. Front Immunol. 2018 Nov 13;9:2610. doi: 10.3389/fimmu.2018.02610. PMID: 30483268; PMCID: PMC6243022.
11. Yunhe Ding, Yunduan Ding, Yaxian Wu, Huiqiong He, Tianhong Yu, Yudong Hu, Depeng Zhang, Kaikai Yu, Xiaozong Li, Lei Sun, Feng Qian*. Isoalantolactone suppresses LPS-induced inflammation by inhibiting TRAF6 ubiquitination and alleviates acute lung injury. Acta Pharmacol Sin. 2019 Jan;40(1):64-74. doi: 10.1038/s41401-018-0061-3. Epub 2018 Jul 16. PMID: 30013035; PMCID: PMC6318348.
12. Yaxian Wu, Huiqiong He, Sirui Liu, Yunhe Ding, Depeng Zhang, Dan Zhang, Lei Sun, Richard D. Ye, Feng Qian*. MK2 mediates macrophage activation and acute lung injury by regulating let-7e miRNA. Am J Physiol Lung Cell Mol Physiol. 2018 Sep 1;315(3):L371-L381. doi: 10.1152/ajplung.00019.2018. Epub 2018 May 17. PMID: 29770701.
13. Depeng Zhang, Xiaozong Li, Yudong Hu, Hongchao Jiang, Yaxian Wu, Yunhe Ding, Kaikai Yu, Huiqiong He, Jingsong Xu, Lei Sun, Feng Qian*. Tabersonine attenuates lipopolysaccharide-induced acute lung injury via suppressing TRAF6 ubiquitination. Biochem Pharmacol. 2018 Aug;154:183-192. doi: 10.1016/j.bcp.2018.05.004. Epub 2018 May 7. PMID: 29746822.
14. Yunduan Song, Xiaozong Li, Yaxian Wu, Yao Shen, Fangfang Liu, Peipai Gao, Lei Sun, Feng Qian*. Emodin alleviates alternatively activated macrophage and asthmatic airway inflammation in a murine asthma model. Acta Pharmacol Sin. 2018 Aug;39(8):1317-1325. doi: 10.1038/aps.2017.147. Epub 2018 Feb 8. PMID: 29417945; PMCID: PMC6289379.
15. Yudong Hu, Kaikai Yu, Gang Wang, Depeng Zhang, Chaoji Shi, Yunhe Ding, Duo Hong, Dan Zhang, Huiqiong He, Lei Sun, Jun-Nian Zheng*, Shuyang Sun*, Feng Qian*. Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell. Biochem Pharmacol. 2018 Apr;150:280-292. doi: 10.1016/j.bcp.2018.02.023. Epub 2018 Feb 21. PMID: 29475060.
16. Ya-xian Wu, Hui-qiong He, Yun-juan Nie, Yun-he Ding, Lei Sun，Feng Qian*. Protostemonine effectively attenuates lipopolysaccharide-induced acute lung injury in mice. Acta Pharmacol Sin. 2018 Jan;39(1):85-96. doi: 10.1038/aps.2017.131. Epub 2017 Oct 19. PMID: 29047459; PMCID: PMC5758663.
17. Hui-qiong He, Ya-xian Wu, Yun-juan Nie, Jun Wang, Mei Ge, Feng Qian*. LYRM03, an ubenimex derivative, attenuates LPS-induced acute lung injury in mice by suppressing the TLR4 signaling pathway. Acta Pharmacol Sin. 2017 Mar;38(3):342-350. doi: 10.1038/aps.2016.141. Epub 2017 Jan 23. PMID: 28112185; PMCID: PMC5342666.
18. Yunjuan Nie, Lei Sun, Yaoyao Yang, Jun Wang, Huiqiong He, Yanhua Chang, Yaxian Wu, Qing Liang, Yudong Hu, Jianwei Zhu, Richard D. Ye, John W. Christman, Feng Qian*. AKT2 Regulates Pulmonary Inflammation and Fibrosis via Modulating Macrophage Activation. J Immunol. 2017 Jun 1;198(11):4470-4480. doi: 10.4049/jimmunol.1601503. Epub 2017 Apr 28. PMID: 28455433.

纵向基金资助情况：
1. 国家自然科学基金面上项目，主持，2024年-2027年（82373875）：受体ChemR23通过ATF5调控成纤维细胞极化介导特发性肺纤维化的机制研究和潜在药靶鉴定。
2. 国家自然科学基金面上项目，主持，2022年-2025年（82173821）：IL-33/ST2诱导FoxP1表达介导巨噬细胞耐受和继发性细菌性肺炎的机制研究及潜在药靶鉴定。
3. 国家自然科学基金面上项目，主持，2020年-2023年（81973329）：E3泛素连接酶AMFR调控巨噬细胞极化介导哮喘的作用机制及潜在靶标研究。
4. 国家自然科学基金面上项目，主持，2018年-2021年（81773741）：蛋白激酶Akt2调控巨噬细胞介导特发性肺纤维化的机制研究与新型药物靶标鉴定。
5. 国家自然科学基金面上项目，主持，2016年-2019年（81573438）：蛋白激酶p38 MAPK调控巨噬细胞极化在特发性肺纤维化中的作用机制研究。
6. 国家自然科学基金面上项目，主持，2014年-2017年（81373424）：蛋白激酶MK2调控嗜中性粒细胞活化介导肝脏缺血再灌注损伤机制与新型药物靶标。
7. 国家重点研发计划“精准医学研究”，分项目负责人，2018年，搭建中国人群头颈部恶性肿瘤个性化PDX平台（2017YFC0908500）。